| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma |
|
Medicine details |
|
| Medicine name | cemiplimab (Libtayo®) |
| Formulation | 350 mg concentrate for solution for infusion |
| Reference number | 3645 |
| Indication | As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation |
| Company | Sanofi |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/02/2019 |
| NICE guidance | TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma |
| Commercial arrangement | PAS |